Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H14O11.2Na |
Molecular Weight | 512.3302 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].OC(COC1=CC=CC2=C1C(=O)C=C(O2)C([O-])=O)COC3=CC=CC4=C3C(=O)C=C(O4)C([O-])=O
InChI
InChIKey=VLARUOGDXDTHEH-UHFFFAOYSA-L
InChI=1S/C23H16O11.2Na/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30;;/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30);;/q;2*+1/p-2
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C23H14O11 |
Molecular Weight | 466.3507 |
Charge | -2 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/75-271_Cromolyn%20Sodium_prntlbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18887slr020_intal_lbl.pdfCurator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf |http://www.rxlist.com/crolom-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/8809432
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/75-271_Cromolyn%20Sodium_prntlbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18887slr020_intal_lbl.pdf
Curator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf |http://www.rxlist.com/crolom-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/8809432
Cromolyn is a mast cell stabilizer. In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells, which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Cromolyn is indicated in the management of patients with mastocytosis, prophylaxis (long-term control) of bronchial asthma, prevention of exercise-induced bronchospasm, prevention and treatment of seasonal and perennial allergic rhinitis The most frequently reported adverse reactions attributed to cromolyn sodium treatment were: throat irritation or dryness, bad taste, cough, wheeze, nausea.
CNS Activity
Sources: www.ncbi.nlm.nih.gov/pubmed/19004805https://www.ncbi.nlm.nih.gov/pubmed/8809432
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1293267 |
|||
Target ID: Chloride channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/1280136 |
19.0 µM [IC50] | ||
Target ID: GO:0070509 |
|||
Target ID: GO:0045576 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12396022 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CROMOLYN SODIUM Approved UseGASTROCROM is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. Launch Date7.6731843E11 |
|||
Preventing | CROMOLYN SODIUM Approved UseCromolyn sodium is a prophylactic agent indicated in the management of patients with bronchial
asthma. Launch Date7.6723198E11 |
|||
Palliative | CROMOLYN SODIUM Approved UseCromolyn sodium is used to prevent and relieve nasal symptoms of hay fever and other nasal allergies. Launch Date7.6723198E11 |
|||
Primary | CROMOLYN SODIUM Approved UseCromolyn sodium ophthalmic solution is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. Launch Date7.6723198E11 |
|||
Preventing | CROMOLYN SODIUM Approved UseTo help prevent asthma attacks. Launch Date7.6723198E11 |
|||
Preventing | NASALCROM Approved UseTo prevent and relieve nasal symptoms of hay fever and other nasal allergies Launch Date8.5216323E11 |
|||
Palliative | OPTREX Approved UseOptrex is used for the prevention and treatment of eye allergies. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.24 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
17.1 mg single, respiratory dose: 17.1 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN cerebrospinal fluid | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.34 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
34.2 mg single, respiratory dose: 34.2 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN cerebrospinal fluid | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
46.69 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
17.1 mg single, respiratory dose: 17.1 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
96.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
34.2 mg single, respiratory dose: 34.2 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
156 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
236 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
338 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
526 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
17.1 mg single, respiratory dose: 17.1 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
34.2 mg single, respiratory dose: 34.2 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
62.4 mg 1 times / day multiple, intranasal Dose: 62.4 mg, 1 times / day Route: intranasal Route: multiple Dose: 62.4 mg, 1 times / day Sources: |
unhealthy, 25 years (range: 5-51 years) n = 45 Health Status: unhealthy Age Group: 25 years (range: 5-51 years) Sex: M+F Population Size: 45 Sources: |
|
200 mg 4 times / day multiple, oral Recommended Dose: 200 mg, 4 times / day Route: oral Route: multiple Dose: 200 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: mastocytosis Age Group: adult Sources: |
|
2 % multiple, ophthalmic |
unhealthy, adult n = 37 Health Status: unhealthy Condition: allergic conjunctivitis Age Group: adult Population Size: 37 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pdf.hres.ca/dpd_pm/00015714.PDF#page=2 Page: 2.0 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
Pro-drugs for the oral delivery of disodium cromoglycate. | 1988 Jan |
|
[Effects of orally available prodrug of cromoglycic acid on collagen-induced arthritis mice]. | 1999 Oct |
|
[A sniffing child]. | 2001 |
|
[Inhalation therapy]. | 2001 Dec |
|
Reasons for and costs of hospitalization for pediatric asthma: a prospective 1-year follow-up in a population-based setting. | 2001 Dec |
|
Determination of sodium cromoglycate in human plasma by liquid chromatography-mass spectrometry in the turbo ion spray mode. | 2001 Dec 25 |
|
Therapy choices beyond antihistamines. Vasomotor rhinitis. | 2001 Nov |
|
Sodium cromoglycate in asthma. | 2001 Nov |
|
Effect of specific immunotherapy versus loratadine on serum adhesion molecules. | 2001 Oct |
|
Antiallergic/antiasthmatic effect of novel antiallergic hexapeptide-95/220 in various experimental models. | 2001 Sep |
|
[Sodium cromoglycate in the treatment of food hypersensitivity in children under 3 years of age]. | 2001 Sep |
|
The importance of control in asthma management: do leukotriene receptor antagonists meet patient and physician needs? | 2001 Sep-Oct |
|
Metering performance of several metered-dose inhalers with different spacers/holding chambers. | 2001 Winter |
|
Topical treatment of pyoderma gangraenosum. | 2002 |
|
Use of intranasal cromolyn sodium for allergic rhinitis. | 2002 Apr |
|
Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. | 2002 Apr 12 |
|
In vitro deposition of the respirable fraction of dry powder inhalations determined by laser diffractometry and inertial impaction. | 2002 Aug |
|
Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. | 2002 Aug |
|
Efficacy and safety of inhaled steroid and cromone treatment in school-age children: a randomized pragmatic pilot study. | 2002 Feb |
|
Using case management to increase antiinflammatory medication use among a managed care population with asthma. | 2002 Feb |
|
Medical management of Cronkhite-Canada syndrome. | 2002 Feb |
|
From khellin to sodium cromoglycate--a tribute to the work of Dr. R. E. C. Altounyan (1922-1987). | 2002 Jan |
|
Assessment of the relationship between hyperalgesia and peripheral inflammation in magnesium-deficient rats. | 2002 Jan 18 |
|
Effects of topical anti-inflammatory and antiallergic eyedrops on prostaglandin E2-induced aqueous flare elevation in pigmented rabbits. | 2002 Jul |
|
Water dynamics in channel hydrates investigated using H/D exchange. | 2002 Jul 25 |
|
Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. | 2002 Jul-Aug |
|
The combination of nebulized sodium cromoglycate and salbutamol in the treatment of moderate-to-severe asthma in children. | 2002 Jun |
|
Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. | 2002 Jun |
|
Improved strategies and new treatment options for allergic rhinitis. | 2002 Jun |
|
Allergic rhinitis remains an important disease. | 2002 Jun |
|
One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma. | 2002 Jun |
|
(S)nifty treatment for pollen allergies. | 2002 Jun |
|
Balancing safety and efficacy in the treatment of pediatric asthma. | 2002 Jun |
|
Generalized bullae in an infant. | 2002 Jun |
|
Management of suspected acute viral upper respiratory tract infection in children with intranasal sodium cromoglicate: a randomised controlled trial. | 2002 Jun 22 |
|
Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma. | 2002 Mar |
|
Inhaled sodium cromoglycate in children with asthma. | 2002 Mar |
|
The effect of disodium cromoglycate, budesonide, and cyclosporin A on interleukin-4, interleukin-5, and interleukin-13 secretions in Der p I-stimulated T cells from house dust mite-sensitive atopic and nonatopic individuals. | 2002 Mar-Apr |
|
Effect of interventions during acute respiratory syncytial virus bronchiolitis on subsequent long term respiratory morbidity. | 2002 May |
|
Ischaemic preconditioning and mast cell histamine release: microdialysis of isolated rat hearts. | 2002 May |
|
Floating a metered-dose inhaler is not an accurate measure of remaining medicine. | 2002 May |
|
Relative lung and systemic bioavailability of sodium cromoglycate inhaled products using urinary drug excretion post inhalation. | 2002 May |
|
Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. | 2002 May |
|
Airway hyperresponsiveness to adenosine induced by lipopolysaccharide in Brown Norway rats. | 2002 May |
|
Long-term management of asthma in children: effectiveness of inhaled corticosteroids compared to other medications. | 2002 Nov |
|
A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. | 2002 Oct |
|
Sodium cromoglycate and doxantrazole are oxygen radical scavengers. | 2002 Oct |
|
Mast cells as a target of rheumatoid arthritis treatment. | 2002 Sep |
|
[Enhancing effects of ion-pair complexes on skin permeation of cromolyn in vitro]. | 2002 Sep |
|
Mast cells mediate the microvascular inflammatory response to systemic hypoxia. | 2003 Jan |
Sample Use Guides
Two metered inhalations four times daily at regular intervals (asthma).
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1375128
Cromoglycate (the active component of cromoglicate lisetil) significantly inhibits histamine release from lung and tonsillar mast cells at 1000 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:18:58 UTC 2023
by
admin
on
Fri Dec 15 15:18:58 UTC 2023
|
Record UNII |
Q2WXR1I0PK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR03AK05
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
||
|
WHO-ATC |
R03AK05
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
||
|
WHO-ATC |
R03AK04
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
||
|
FDA ORPHAN DRUG |
8285
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
||
|
FDA ORPHAN DRUG |
497415
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
||
|
FDA ORPHAN DRUG |
1183
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
||
|
NCI_THESAURUS |
C29714
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
||
|
WHO-VATC |
QR03AK04
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Q2WXR1I0PK
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
Q2WXR1I0PK
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
15826-37-6
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
27503
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
D004205
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
1150502
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
DBSALT000985
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
C28946
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
DTXSID7044554
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
CROMOLYN SODIUM
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | Description: A white, crystalline powder; odourless. Solubility: Freely soluble in water; slightly soluble in methanol R; very slightly soluble in ethanol (~750 g/l) TS; practically insolublein ether R. Category: Antiasthmatic drug. Storage: Sodium cromoglicate should be kept in a tightly closed container, protected from light. Additional information: Sodium cromoglicate is hygroscopic. Definition: Sodium cromoglicate contains not less than 98.0% and not more than 101.0% of C23H14Na2O11, calculated with reference to the dried substance. | ||
|
m3851
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | Merck Index | ||
|
128458
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
SUB12286MIG
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
3538
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | RxNorm | ||
|
100000092054
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
SUB126228
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
ALTERNATIVE | |||
|
CHEMBL428880
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
109500
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY | |||
|
239-926-7
Created by
admin on Fri Dec 15 15:18:58 UTC 2023 , Edited by admin on Fri Dec 15 15:18:58 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |